New Route of Administration for Millenium's VELCADE (bortezomib)

01 Feb 2012 8:33 AM | Lori Aubrey (Administrator)
The U.S. Food and Drug Administration (FDA) has approved VELCADE for subcutaneous administration in patients with multiple myeloma (MM) and relapsed mantle cell lymphoma (MCL).

View this and other FDA Approvals on the dedicated FDA Approvals page under the Resources section of our website.


Comments

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948
info@nnecos.org

This website brought to you by:


Powered by Wild Apricot Membership Software